BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for C Betschart

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs).EBI
Novartis Institutes For Biomedical Research
Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.EBI
Novartis Institutes For Biomedical Research
New chemotypes for cathepsin K inhibitors.EBI
Novartis Institutes For Biomedical Research
Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors.EBI
University of Montreal
Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application.EBI
Novartis Institutes For Biomedical Research
Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo.EBI
Novartis Institutes For Biomedical Research
 
Studies on the active conformation of NK1 antagonist CGP 49823. Part 1. Synthesis of conformationally restricted analogs.EBI
TBA
 
SAR of 2-benzyl-4-aminopiperidines NK1 antagonists. Part 21. synthesis of CGP 49823EBI
TBA
Novel scaffold for cathepsin K inhibitors.EBI
Novartis Institutes For Biomedical Research
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases.EBI
Novartis Institutes for Biomedical Research
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an EBI
Novartis Institutes For Biomedical Research
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.EBI
Genomics Institute of The Novartis Research Foundation
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.EBI
Genomics Institute of The Novartis Research Foundation
Structure-Based and Property-Driven Optimization of EBI
Global Discovery Chemistry
Substituted pyridines as inhibitors of human immunodeficiency virus replicationBDB
Viiv Healthcare UK (NO.5)
Inhibitors of lysine specific demethylase-1BDB
Celgene Quanticel Research
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.BDB
Glaxosmithkline
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.BDB
Astrazeneca
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.BDB
Glaxosmithkline